Strategy Used $300 Million to Backstop Bitcoin Purchases
Strategy, formerly MicroStrategy, used $300 million to shore up liquidity while continuing to fund Bitcoin purchases....
Articles — Page 600
Toy Story 5 Breaks Box Office Records with Record Opening
Toy Story 5 opened to a record $312 million worldwide, setting a franchise benchmark while reminding investors that b...
Insilico Medicine, Biopharmaceuticals Strike: AI Drug Deal Heads Toward $2.5B
Insilico Medicine and SK Biopharmaceuticals unveiled a milestone collaboration worth up to $2.5 billion to develop ne...
Fired Universities Wisconsin President Blindsided, No Reason
The University of Wisconsin System fired its president in a unanimous vote after a brief closed-door meeting, leaving...
Mexico City’s Unofficial Duck Disrupts Presidential Briefing
A street vendor’s duck strolled into a presidential briefing in Mexico City, becoming an instant social-media sensati...
Planet’s Heat Bill Comes Due as One Billion Face Heat
A new global study links warming to a sharp rise in extreme heat stress affecting about one billion more people. The ...
Million Horror Film Sparks Summer Comeback for 30-Year-Old Franchise
A $1 million horror film defies expectations while a 30-year-old franchise returns with a bold new installment, deliv...
Barbara Bain Says Mission: How a Role Shapes Wealth & Image
A single screen image can powerfully influence how audiences see you—and how you manage money. This article shows how...
Jana Kramer Says Almost: Financial Planning Under Pressure
In the demanding world of entertainment and performance, schedules are harsh and pay can be unpredictable. This artic...
Spacex Over. History Says: What Investors Should Do Next
SpaceX’s IPO spectacle invites big questions. History shows that the right move isn’t chasing the initial hype, but b...
Nebius Stock: Already Around 240% This Year—Is It Worth Buying?
Nebius Group has rocketed more than 240% this year. Before you jump in, learn how to weigh momentum against fundament...
Reasons Bristol Myers Squibb Stock: 3 Key Arguments
Want to know if Bristol Myers Squibb is worth a spot in your portfolio? This deep dive highlights three core reasons ...